Evidence map›Paper›PMID 37048053›Full record

ArticleCells2023

S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720.

Fabrice J F Laroche, Sheng Li, Ning Shen, Soo Kyung Hwang, Gina Nguyen, Wenling Yu, Chen Khuan Wong, Ryan J Quinton, Jason N Berman, Ching-Ti Liu and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Synthesis and Biological Evaluation ofMolecules (Basel, Switzerland) · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 3 countries.

Fabrice J F LarocheDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Sheng LiDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Ning ShenDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Soo Kyung HwangDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Gina NguyenDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Wenling YuDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Chen Khuan WongBiomedical Genetics Section, Department of Medicine, Department of Pathology and Laboratory Medicine, Genetics and Genomics Graduate Program, Cancer Center, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Ryan J QuintonDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Jason N BermanChildren's Hospital of Eastern Ontario Research Institute, Departments of Pediatrics and Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8L1, Canada.ORCID 0000-0002-4053-6067
Ching-Ti LiuDepartment of Biostatistics, School of Public Health, Boston University, Boston, MA 02118, USA.ORCID 0000-0002-0703-0742
Anurag SinghDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Neil J GanemDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Sam ThiagalingamBiomedical Genetics Section, Department of Medicine, Department of Pathology and Laboratory Medicine, Genetics and Genomics Graduate Program, Cancer Center, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Hui FengDepartments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.ORCID 0000-0003-1318-821X
Boston University · USUniversity of Ottawa · CA

Funding

Illuminating Dynamic Receptor Clustering in the Epidermal Growth Factor Receptor Signal Transduction Pathway Using Plasmon CouplingR01CA138509 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI Bjoern Markus Reinhard · 2009 to 2026
$5.9M
Regulation of cell growth and proliferation by the Hippo pathwayR01GM117150 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI NEIL J. GANEM · 2016 to 2026
$2.4M
The Role of DLST in LeukemogenesisR01CA215059 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2018 to 2022
$2.0M
"Oncorequisite" Genes in MYC-mediated TransformationR00CA134743 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2012 to 2014
$712k
Defining lineage-specific determinants of K-Ras "addiction" in human cancersR00CA149169 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SINGH, ANURAG · 2012 to 2014
$710k
Dissecting the metastasis suppressor complex to identify colon cancer biomarkersR21CA165707 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI THIAGALINGAM, SAM · 2013 to 2014
$386k
The Role of DLST in LeukemogenesisR56CA215059 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2017 to 2017
$376k
"Oncorequisite" Genes in MYC-mediated TransformationK99CA134743 · NCI · DANA-FARBER CANCER INST · PI FENG, HUI · 2009 to 2010
$282k
Defining lineage-specific determinants of K-Ras "addiction" in human cancersK99CA149169 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SINGH, ANURAG · 2010 to 2011
$268k
NCI NIH HHS K99 CA134743NCI NIH HHS K99 CA149169NCI NIH HHS R00 CA134743NCI NIH HHS R00 CA149169NCI NIH HHS R01 CA138509NCI NIH HHS R01 CA215059NCI NIH HHS R21 CA165707NCI NIH HHS R56 CA215059NIGMS NIH HHS R01 GM117150
6 · The paper itself

Abstract

Hyperactive sphingosine 1-phosphate (S1P) signaling is associated with a poor prognosis of triple-negative breast cancer (TNBC). Despite recent evidence that links the S1P receptor 1 (S1P1) to TNBC cell survival, its role in TNBC invasion and the underlying mechanisms remain elusive. Combining analyses of human TNBC cells with zebrafish xenografts, we found that phosphorylation of S1P receptor 1 (S1P1) at threonine 236 (T236) is critical for TNBC dissemination. Compared to luminal breast cancer cells, TNBC cells exhibit a significant increase of phospho-S1P1 T236 but not the total S1P1 levels. Misexpression of phosphorylation-defective

Indexed as

Fingolimod HydrochlorideSphingosine-1-Phosphate ReceptorsTriple Negative Breast NeoplasmsAnimalsHumansPhosphorylationProto-Oncogene Proteins c-aktReceptors, LysosphingolipidThreonineZebrafishFingolimod HydrochlorideProto-Oncogene Proteins c-aktReceptors, LysosphingolipidS1PR1 protein, humanSphingosine-1-Phosphate ReceptorsThreonineFTY720invasivenessMK2206sphingosine 1-phosphate receptor 1threonine 236 phosphorylationtriple-negative breast cancerzebrafish

Identifiers

PMID37048053
PMCPMC10093541
OpenAlexW4360857826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.